lung cancer image

References

    1. 
  • Sandler AB, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer. N Engl J Med 2006;355:2542-50.
    • 2. 
  • Pirker R, Szczesna A, von Pawel J, et al. FLEX: A randomized, multicenter, phase III study of cetuximab in combination with cisplatin/vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2008; 26(18S):1006s (abstr 3).
    • 3. 
  • Fidias PM, Dakhil SR, Lyss AP, et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2009;27:591-8.
    • 4. 
  • Belani CP, Brodowicz T, Ciuleanu T, et al. Maintenance pemetrexed plus best supportive care versus placebo plus BSC: A randomized phase III study in advanced non-small cell lung cancer. J Clin Oncol 2009;27(18S):(abstr 8000).
    • 5. 
  • Cappuzzo F, Ciuleanu T, Stelmakh L, et al on behalf of the SATURN Investigators. SATURN: A double-blind, randomized, phase III study of maintenance erlotinib versus placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced NSCLC. J Clin Oncol 2009;27(18S):15s (abstr 8001).
    • 6. 
  • Miller VA, O'Connor P, Soh S, et al for the ATLAS Investigators. A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 2009;27(18S) (abstr LBA8002).
    • 7. 
  • Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced stage non-small cell lung cancer. J Clin Oncol 2008;26: 3543-51.
    • 8. 
  • Patel JD, Hensing TA, Rademaker A, et al. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for non-squamous non-small-cell lung cancer. J Clin Oncol 2009 May 11.
    • 9. 
  • Mok T, Wu Y-L, Thongprasert S, et al. Phase III, randomised, open-label, first-line study of gefitinib vs carboplatin/paclitaxel in clinically selected patients with advanced non-small cell lung cancer (IPASS). In: European Society for Medical Oncology; 33rd ESMO conference, Stockholm, Sweden 2008 (abstr 1).
    • 10. 
  • Lebanony D, Benjamin H, Gilad S, et al. Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from non-squamous non-small cell lung carcinoma. J Clin Oncol 2009;27:2030–7.
    • 11. 
  • Ferrara N, Hillan KJ, Gerber HP, et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004;3:391-400.
    • 12. 
  • Presta LG, Chen H, O'Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997;57:4593-9.
    • 13. 
  • Avastin® (bevacizumab) prescribing information. Genentech, Inc, South San Francisco, California, 2008.
    • 14. 
  • Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004;22:2184–91.
    • 15. 
  • Ramalingam SS, Dahlberg SE, Langer CJ, et al. Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol 2008;26:60–5.
    • 16. 
  • Manegold C, von Pawel J, Zatloukal P, et al. Randomised, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naive patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): BO17704. J Clin Oncol 2007;25(suppl) (abstr LBA7514)
    • 17. 
  • Reck M. von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small cell lung cancer: AVAiL. J Clin Oncol 2009; 27(8):1227-34.
    • 18. 
  • Shaked Y, Henke E, Roodhart JM, et al. Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell 2008;14:263-73.
    • 19. 
  • Folkman, J. Angiogenesis inhibitors: A new class of drugs. Cancer Biol Ther 2003;2(suppl 1):S127–33.
    • 20. 
  • Willett CG, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has anti-vascular effects in human rectal cancer. Nat Med 2004;10:145–7.
    • 21. 
  • Herbst RS, Bunn PA Jr. Targeting the epidermal growth factor receptor in non-small cell lung cancer. Clin Cancer Res 2003;9:5813-24.
    • 22. 
  • Baselga J, Arteaga CL. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 2005;23:2445–59.
    • 23. 
  • Hubbard SR, Miller WT. Receptor tyrosine kinases: Mechanisms of activation and signaling. Curr Opin Cell Biol 2007;19:117-23.
    • 24. 
  • Giaccone G, Herbst RS, Manegold C, et al Gefitinib in combination with gemcitabine and cisplatin in advanced non-small cell lung cancer: A phase III trial-INTACT1. J Clin Oncol 2004:22:777–8.
    • 25. 
  • Gatzemeier U, Pluzanska A, Szczesna A, et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small cell lung cancer: The Tarceva Lung Cancer Investigation Trial. J Clin Oncol 2007;25:1545-52.
    • 26. 
  • Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small cell lung cancer: A phase III trial-INTACT 2. J Clin Oncol 2004;22:785–94.
    • 27. 
  • Herbst RS, Prager D, Hermann R, et al. TRIBUTE Investigator Group. TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005;23:5892–9. 14
    • 28. 
  • Thienelt CD, Bunn PA Jr, Hanna N, et al. Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer. J Clin Oncol 2005;23:8786–93.
    • 29. 
  • Rosell R, Robinet G, Szczesna A, et al. Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. Ann Oncol 2008;19:362–9.
    • 30. 
  • Robert F, Blumenschein G, Herbst RS, et al. Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemo-therapy-naive advanced non-small cell lung cancer. J Clin Oncol 2005;23:9089–96.
    • 31. 
  • Lynch T, Patel T, Dreisbach L, et al. A randomized multicenter phase III study of cetuximab (Erbitux(R)) in combination with Taxane/Carboplatin versus Taxane/Carboplatin alone as first-line treatment for patients with advanced/metastatic non-small cell lung cancer (NSCLC): B3-03. J Thor Onc 2007;2:S340–1.
    • 32. 
  • Crawford J, Sandler AB, Hammond LA, et al. ABX-EGF in combination with paclitaxel and carboplatin for advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2004;22(suppl) (abstr 7083).
    • 33. 
  • Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology. American Society of Clinical Oncology treatment of unresectable non–small cell lung cancer guideline: Update 2003. J Clin Oncol 2004;22:330-53.
    • 34. 
  • Smith IE, O'Brien ME, Talbot DC, et al. Duration of chemotherapy in advanced non–small cell lung cancer: A randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol 2001;19:1336-43.
    • 35. 
  • Socinski MA, Schell MJ, Peterman A, et al. Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non–small cell lung cancer. J Clin Oncol 2002;20:1335-43.
    • 36. 
  • Hida T, Okamoto I, Kashii T, et al. Randomized phase III study of platinum-doublet chemotherapy followed by gefitinib versus continued platinum-doublet chemotherapy in patients (pts) with advanced non-small cell lung cancer (NSCLC): Results of West Japan Thoracic Oncology Group trial (WJTOG. J Clin Oncol 2008;26:LBA8012 (abstr).
    • 37. 
  • Adjei AA. Pemetrexed (Alimta): A novel multitargeted antifolate agent. Exp Rev Anticancer Ther 2003;3:145–56.
    • 38. 
  • Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-97.
    • 39. 
  • Peterson P, Park K, Fossella F, et al. Is pemetrexed more effective in patients with non-squamous histology? A retrospective analysis of a phase III trial of pemetrexed versus docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC). Eur J Cancer 2007;(suppl 5):363-4.
    • 40. 
  • Zielinski CC, Yang S, Santoro A, et al. Tolerability of pemetrexed versus placebo as a maintenance therapy in advanced non-small cell lung cancer: Evidence from a large randomized study. J Clin Oncol 2008;26:8060 (abstr).